Program Results

For results from our European programs click here.

Recurring Programs

International Outstanding Achievement Award 2018 | 2016
Recognizes exceptional investigators who have made significant advances in accelerating the development of therapeutics for neurodegenerative diseases of aging through translational research. This award is given every other year to a researcher in Canada.

Rapid Response 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012
Seed funding (up to $300,000 for up to 18 months) for high-risk, high-reward, novel ideas.

Transformational Research 2020 |2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013
Larger, longer grants (up to $1.5m for up to 3 years) for transformational work including international collaborations.

Early Phase Clinical Trials 2018/2019 | 2015 | 2014
Larger, longer grants (up to $1.5m for up to 4 years) for projects focusing on Phase I or IIa clinical trials.

International Fellowships 2016 | 2015
Funding ($60,000 per year prorated as needed) to advance research on neurodegenerative disease of aging abroad.

Advisor Fellowships 2019 |2018 | 2017 | 2016 | 2015 | 2014
Targeted funding for postdoctoral researchers to complete one or two year projects in the laboratories of our scientific advisory committee members.

One-Time Programs

Big Ideas: Canada 2019
The Big Ideas: Canada 2019 program supports large-scale, pivotal projects to significantly advance research in the field of neurodegenerative diseases of aging.

Canada: ALS 2016
Providing support for translational research that accelerates the development of safe and effective therapies for Amyotrophic Lateral Sclerosis (ALS).

Targeted Diseases: FTD & PSP 2014
The goal of the Targeted Diseases program is to provide targeted support for high impact, translational research in frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP).

Collaborative Programs

Biomarkers Against Neurodegenerative Diseases 2015 | 2014
The main objective of BAND is to stimulate analyses across Alzheimer’s disease (AD), Parkinson’s disease (PD), and other neurodegenerative diseases to increase understanding of pathogenesis similarities and differences.  Applicants may request funding for up to two years and $150,000 in total costs.

Mechanisms of Cellular Death in Neurodegeneration 2015
The MCDN Initiative invites research proposals that will explore brain cell death mechanisms in neurodegenerative diseases. MCDN funds either a consortium of investigative teams or individual team-based projects ranging between USD$100,000-$1,250,000.

Systemic Synuclein Sampling Study (S4) 2015
The search for safe, reliable, and inexpensive biomarkers of Parkinson’s disease (PD) remains a major unmet clinical need and is currently a high priority among PD researchers.  S4 brings together prominent PD research centers from Canada and the United States to characterize alpha-synuclein distribution in multiple tissues and biofluids from PD patients. By employing standardized tissue collection and processing techniques across all sites, S4 is the largest evaluation of PD patient biomarkers, to date.

The W. Garfield Weston Foundation – Alzheimer’s Drug Discovery Foundation (ADDF) – Canada 2011
Three-year grant to support clinical trials for Alzheimer’s therapeutics through the ADDF-Canada’s Program to Accelerate Clinical Trials (PACT). Download Press Release

The W. Garfield Weston Foundation – Brain Canada Foundation Multi-Investigator Research Initiative (MIRI) 2011 
Three-year team based grants for transformative grants for research aimed at improving our understanding of human nervous system function and dysfunction and its impact on health.  Download Press Release

The W. Garfield Weston Foundation – Michael J. Fox Foundation 2011
Funding for 8 teams across Canada working on promising treatments for Parkinson’s disease.